Premier Psych TMS has launched a personalized medicine test consisting of a simple cheek swab, for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.
The ADHD lab test analyzes variations in three genes that influence how a patient might metabolize certain medications used to treat ADHD in children and adults. Understanding a patient’s unique genomic profile can help a clinician individualize a patient’s medication selection and avoid side effects that often occur with these medications. The test provides objective, evidence-based information for clinicians to personalize medication selection for each patient.
ADHD diagnoses increased 66 percent from 6.2 million in 2000 to 10.4 million in 2010, according to a study published in the March/April 2012 issue of Academic Pediatrics. ADHD is the most common childhood disorder and can continue into adulthood.
Symptoms of ADHD include an inability to stay focused or pay attention, difficulty controlling behavior, and hyperactivity.
Premier Psych providers are very pleased with the results of the mood, depression, and anxiety pharmacogenomics lab test that has been available for the past six months.
For more information Premier Psych TMS, please visit them online at www.premierpsych.com.